Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on April 17, 2015, covering events that occurred on April 13, 2015. The filing primarily addresses corporate governance changes, specifically the adoption of a new equity incentive plan and the appointment of principal officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on equity compensation and personnel matters rather than financial performance.
Material Changes
- Adoption of 2015 Equity Incentive Plan: The Board adopted a new plan allowing for the grant of stock options, restricted stock, and cash awards. The total share reserve is 80,000,000 shares, which includes 32,907,135 shares remaining from the 2007 Prior Plan. No further shares will be issued under the Prior Plan.
- Director Stock Options: Each non-employee director was granted 350,000 10-year stock options with an exercise price of $1.17 per share. These vest in four equal annual increments starting April 13, 2016.
- CFO Stock Options: Gerald McGuire, Chief Financial Officer, was granted 200,000 10-year options with identical vesting terms to the directors.
- Employment Agreement: The Company entered into an at-will employment agreement with Director Gary Wilcox, setting his compensation at $100,000 per year.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, or specific risk factors beyond the standard vesting conditions tied to continued service.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the new 2015 Equity Incentive Plan (80,000,000) and the dilution impact relative to the current share count.
- Confirm the exercise price of $1.17 per share for the newly granted options and compare it to the current market price.
- Review the vesting schedule for the 350,000 options granted to each non-employee director and the 200,000 options granted to the CFO.
- Assess the implications of the new $100,000 annual compensation for Director Gary Wilcox.